B+
Bull case
25%
Probability
Target price
$105.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
GMED
Globus MedicalANYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$88.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$62.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-12
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+100.0
Score
AI commentary
Company-specific news tone is moderately positive following the CE mark and the earlier Q2 EPS-guidance increase. The $74.19 anchor does not establish the market reaction attributable to either event. Social coverage is absent, and options skew, short interest, employee ratings and verified analyst revisions are unavailable; zero values in those fields indicate missing evidence rather than neutral readings. The thesis therefore remains a fundamentals-led monitoring view.
RankAlpha Sentiment Codex - 2026-09-12
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventFull-year 2026 guidance deliveryHigh impact
Globus reaffirmed 2026 revenue guidance of $3.18-$3.22 billion and raised non-GAAP diluted EPS guidance to $4.95-$5.05 from $4.70-$4.80. Delivery now depends on continued share gains, margin expansion and synergy realization through year-end. [#SEC-8K-2026-08-06]
2027-08-06catalystSpine share gains and operating leverageHigh impact
Q2 included 7% US Spine growth, 14% reported International Spine growth and 200 basis points of adjusted gross-margin expansion; management described a fifth consecutive quarter of above-market US Spine growth. Sustaining these trends would support earnings growth beyond the current guidance period. [#SEC-8K-2026-08-06]
2027-09-03catalystExcelsius3D European commercializationHigh impact
The September 3 CE mark permits commercial sale of Excelsius3D in the EU and UK, expanding the Excelsius ecosystem by combining intraoperative imaging with ExcelsiusGPS robotic navigation. Hospital adoption and revenue contribution remain unquantified. [#IR-2026-09-03]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-12 • Updated nightlySource: Internal modelMethodology